Opendata, web and dolomites

AVITAG SIGNED

Alphaviral Immunotherapy against Glioblastoma

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "AVITAG" data sheet

The following table provides information about the project.

Coordinator
UPPSALA UNIVERSITET 

Organization address
address: VON KRAEMERS ALLE 4
city: UPPSALA
postcode: 751 05
website: www.uu.se

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website https://www.igp.uu.se/research/clinical_immunology/magnus_essand/
 Total cost 185˙857 €
 EC max contribution 185˙857 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2015
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2016
 Duration (year-month-day) from 2016-05-01   to  2018-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UPPSALA UNIVERSITET SE (UPPSALA) coordinator 185˙857.00

Map

 Project objective

Alphaviral Immunotherapy against Glioblastoma

Glioblastomas (GBM) are the most frequent type of primary brain tumours with no treatment or cure available. Despite the current standard care, GBMs remain 100% fatal with median survival of patients for only 12 - 15 months. Thus, there is an urgent need for novel effective therapies. Among the emerging new therapeutic approaches is oncolytic virotherapy with replicative viruses that kill cancer cells. During his PhD studies, the applicant researcher, Miika Martikainen, has engineered novel tumour-targeted replicative alphavirus that shows promising therapeutic response in a syngeneic orthotropic mouse model for human GBM. As the next step, the applicant seeks to join Professor Magnus Essand’s group at the Uppsala University to conduct his postdoctoral research project that aims to development of clinically relevant oncolytic immunovirotherapy against GBM. To achieve this aim, previously unappreciated potency of Alphaviral oncolytic virotherapy is combined with synergistic immunotherapy with dendritic cell vaccination and/or adenoviruses. A detailed analysis of relevant immune responses associated with the therapy efficacy will be conducted to allow clinical translation of the results. The state-of-the-art methods available and the training received during the fellowship at host laboratory and secondments will arm the applicant with the skills and knowledge that allow him to establish a career as independent research scientist in a field that aims to develop novel ways to treat severe forms cancer.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AVITAG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AVITAG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MIGPSC (2018)

Shaping the European Migration Policy: the role of the security industry

Read More  

Long-term migration (2019)

Immigration, Attitudes of Natives and Immigrants Assimilation

Read More  

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More